4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 159.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 820,069 shares of the company's stock after buying an additional 504,086 shares during the period. JPMorgan Chase & Co. owned approximately 1.77% of 4D Molecular Therapeutics worth $4,568,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of FDMT. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in 4D Molecular Therapeutics by 168.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,041 shares of the company's stock worth $166,000 after acquiring an additional 17,576 shares in the last quarter. EntryPoint Capital LLC lifted its stake in shares of 4D Molecular Therapeutics by 126.5% during the 4th quarter. EntryPoint Capital LLC now owns 55,539 shares of the company's stock worth $309,000 after acquiring an additional 31,020 shares during the last quarter. Vanguard Group Inc. increased its stake in 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after purchasing an additional 92,791 shares during the period. Fox Run Management L.L.C. purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth $69,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in 4D Molecular Therapeutics in the fourth quarter worth $48,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on FDMT shares. BMO Capital Markets lowered 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and cut their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. Bank of America cut their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Leerink Partners cut their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday, April 8th. Finally, Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $26.71.

4D Molecular Therapeutics Stock Down 1.8 %

Shares of NASDAQ FDMT traded down $0.06 during trading on Thursday, hitting $3.36. The company had a trading volume of 53,722 shares, compared to its average volume of 828,973. The stock has a fifty day simple moving average of $3.68 and a two-hundred day simple moving average of $5.75. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $28.93. The firm has a market capitalization of $155.57 million, a price-to-earnings ratio of -1.17 and a beta of 2.89.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, analysts anticipate that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.